MedPath

Radiation Therapy to Prevent Brain Metastases in Patients With Previously Treated Extensive-Stage Small Cell Lung Cancer

Phase 3
Completed
Conditions
Lung Cancer
Registration Number
NCT00016211
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Brief Summary

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Radiation therapy to the brain may be effective in preventing brain metastases. It is not yet known if radiation therapy is effective following chemotherapy in preventing brain metastases.

PURPOSE: Randomized phase III trial to determine the effectiveness of radiation therapy in preventing brain metastases in patients who have received chemotherapy for extensive-stage small cell lung cancer.

Detailed Description

OBJECTIVES:

* Compare the incidence of, and time to, symptomatic brain metastases in patients with previously treated extensive stage small cell lung cancer treated with prophylactic cranial irradiation vs no further therapy.

* Compare the quality of life and survival of these patients.

* Determine the toxicity of this regimen in these patients.

* Determine the health economics associated with this study.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating center and performance status. Patients are randomized to 1 of 2 treatment arms.

* Arm I: Within 5 weeks after completion of prior chemotherapy, patients undergo prophylactic cranial irradiation once daily for 5-12 days.

* Arm II: Patients receive no further therapy after completion of prior chemotherapy.

Quality of life is assessed at baseline, 6 weeks, every 3 months for 1 year, and then every 6 months thereafter.

Patients are followed at 6 weeks, every 3 months for 1 year, and then every 6 months thereafter.

PROJECTED ACCRUAL: A total of 287 patients will be accrued for this study within 3 years.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
287
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Time to symptomatic brain metastases measured by Logrank at 6 weeks, every 3 months in year 1, and then every 6 months
Secondary Outcome Measures
NameTimeMethod
Quality of life assessed by EORTC QLQ-C30 and EORTC BN-20 at baseline, 6 weeks, every 3 months in year 1, and then every 6 months
Toxicity assessed by NCI CTC v2.0 during treatment, at 6 weeks, every 3 months in year 1, and then every 6 months
Survival measured by Logrank at 6 weeks, every 3 months in year 1, and then every 6 months

Trial Locations

Locations (49)

University of Kaposvar

🇭🇺

Kaposvar, Hungary

Cancer Research Centre at Weston Park Hospital

🇬🇧

Sheffield, England, United Kingdom

Ziekenhuis Netwerk Antwerpen Middelheim

🇧🇪

Antwerp, Belgium

Cazk Groeninghe - Campus Maria's Voorzienigheid

🇧🇪

Kortrijk, Belgium

Hopital de Jolimont

🇧🇪

Haine Saint Paul, Belgium

Universiteit Gent

🇧🇪

Ghent, Belgium

National Cancer Institute of Egypt

🇪🇬

Cairo, Egypt

Centre Hospitalier Regional de la Citadelle

🇧🇪

Liege, Belgium

Clinique Saint-Joseph

🇧🇪

Liege, Belgium

Institut Gustave Roussy

🇫🇷

Villejuif, France

Universitaetsklinikum Hamburg-Eppendorf

🇩🇪

Hamburg, Germany

Ospedale Santa Croce

🇮🇹

Cuneo, Italy

Rambam Medical Center

🇮🇱

Haifa, Israel

Istituto Nazionale per la Ricerca sul Cancro

🇮🇹

Genoa (Genova), Italy

Vrije Universiteit Medisch Centrum

🇳🇱

Amsterdam, Netherlands

Arnhems Radiotherapeutisch Instituut

🇳🇱

Arnhem, Netherlands

Azienda Ospedaliera Di Parma

🇮🇹

Parma, Italy

Radiotherapeutisch Instituut-(Riso)

🇳🇱

Deventer, Netherlands

Academisch Medisch Centrum at University of Amsterdam

🇳🇱

Amsterdam, Netherlands

Radiotherapeutisch Instituut Friesland

🇳🇱

Leeuwarden, Netherlands

University Medical Center Groningen

🇳🇱

Groningen, Netherlands

Leiden University Medical Center

🇳🇱

Leiden, Netherlands

University Medical Center Rotterdam at Erasmus Medical Center

🇳🇱

Rotterdam, Netherlands

Nijmegen Cancer Center at Radboud University Medical Center

🇳🇱

Nijmegen, Netherlands

Medical University of Gdansk

🇵🇱

Gdansk, Poland

Dr. Bernard Verbeeten Instituut

🇳🇱

Tilburg, Netherlands

Erasmus MC - Sophia Children's Hospital

🇳🇱

Rotterdam, Netherlands

Marmara University Hospital

🇹🇷

Istanbul, Turkey

Princess Royal Hospital

🇬🇧

Hull, England, United Kingdom

Cookridge Hospital at Leeds Teaching Hospital NHS Trust

🇬🇧

Leeds, England, United Kingdom

Leicester Royal Infirmary

🇬🇧

Leicester, England, United Kingdom

Christie Hospital N.H.S. Trust

🇬🇧

Manchester, England, United Kingdom

Clatterbridge Centre for Oncology NHS Trust

🇬🇧

Merseyside, England, United Kingdom

Mount Vernon Cancer Centre at Mount Vernon Hospital

🇬🇧

Northwood, England, United Kingdom

Northern Centre for Cancer Treatment at Newcastle General Hospital

🇬🇧

Newcastle Upon Tyne, England, United Kingdom

Nottingham City Hospital NHS Trust

🇬🇧

Nottingham, England, United Kingdom

Royal Shrewsbury Hospital

🇬🇧

Shrewsbury, England, United Kingdom

Southampton General Hospital

🇬🇧

Southampton, England, United Kingdom

Royal Marsden NHS Foundation Trust - Surrey

🇬🇧

Sutton, England, United Kingdom

Southend NHS Trust Hospital

🇬🇧

Westcliff-On-Sea, England, United Kingdom

Ninewells Hospital and Medical School

🇬🇧

Dundee, Scotland, United Kingdom

Western Infirmary

🇬🇧

Glasgow, Scotland, United Kingdom

Nevill Hall Hospital

🇬🇧

Gwent, Wales, United Kingdom

Royal Gwent Hospital

🇬🇧

Newport Gwent, Wales, United Kingdom

Raigmore Hospital

🇬🇧

Inverness, Scotland, United Kingdom

Bank Of Cyprus Oncology Centre

🇨🇾

Nicosia, Cyprus

Edinburgh Cancer Centre at Western General Hospital

🇬🇧

Edinburgh, Scotland, United Kingdom

Bristol Haematology and Oncology Centre

🇬🇧

Bristol, England, United Kingdom

Velindre Cancer Center at Velindre Hospital

🇬🇧

Cardiff, Wales, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath